ETF Battles: Which Pharmaceutical ETF Should You Buy? Watch PPH Vs. PJP Vs. XPH

Image Source: Unsplash

In this episode of ETF Battles, I referee an audience-requested triple-header contest between a trio of pharmaceutical ETFs from Invesco (PJP), SPDR State Street Global Advisors (XPH), and VanEck (PPH).

David Dierking with TheStreet.com and Tom Psarofagis with Bloomberg Intelligence judge the ETF match-up, sharing their investing research insights. Each ETF is judged against the other in key categories like cost, exposure strategy, performance, and a mystery category. Find out who wins the battle.

00:15:21